103 results on '"Briers E"'
Search Results
2. Patient-reported fatigue up to five years after radiotherapy in an international multicentre cohort study of men with non-metastatic prostate cancer
- Author
-
Heumann, P, Rosas, JC, Aguado-Barrera, ME, Azria, D, Briers, E, Kaaks, R, López-Pleguezuelos, C, Rancati, T, Rattay, T, Rosenstein, B, Sperk, E, Stobart, H, Talbot, C, Vega, A, Ward, T, Webb, A, West, CM, Chang-Claude, J, Seibold, P, Heumann, P, Rosas, JC, Aguado-Barrera, ME, Azria, D, Briers, E, Kaaks, R, López-Pleguezuelos, C, Rancati, T, Rattay, T, Rosenstein, B, Sperk, E, Stobart, H, Talbot, C, Vega, A, Ward, T, Webb, A, West, CM, Chang-Claude, J, and Seibold, P
- Published
- 2024
3. Understanding the barriers to prostate cancer population-based early detection programs: The PRAISE-U BEST survey
- Author
-
Beyer, K., primary, Leenen, R., additional, Venderbos, L.D.F., additional, Helleman, J., additional, Denijs, F., additional, Gomez Rivas, J., additional, Vasilyeva, V., additional, Briers, E., additional, Chloupkova, R., additional, Májek, O., additional, Frese, T., additional, Vilaseca, J., additional, Vinker, S., additional, Vynckier, P., additional, Annemans, L., additional, Basu, P., additional, Chandran, A., additional, Van Den Bergh, R.C.N., additional, Collen, S., additional, Van Poppel, H., additional, and Roobol, M.J., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Why is there a need to re-think prostate cancer early detection?
- Author
-
Beyer, K., primary, Leenen, R., additional, Venderbos, L.D.F., additional, Denijs, F., additional, Helleman, J., additional, Chloupkova, R., additional, Májek, O., additional, Briers, E., additional, Vasilyeva, V., additional, Gomez Rivas, J., additional, Annemans, L., additional, Vynckier, P., additional, Basu, P., additional, Chandran, A., additional, Van Den Bergh, R.C.N., additional, Collen, S., additional, Stenzl, A., additional, Van Poppel, H., additional, and Roobol, M.J., additional
- Published
- 2024
- Full Text
- View/download PDF
5. A systematic review of the efficacy and toxicity of brachytherapy boost combined with external beam radiotherapy for nonmetastatic prostate cancer
- Author
-
Tilki, Derya, Slevin, F.; Zattoni, F.; Checcucci, E.; Cumberbatch, M.G.K.; Nacchia, A.; Cornford, P.; Briers, E.; De Meerleer, G.; De Santis, M.; Eberli, D.; Gandaglia, G.; Gillessen, S.; Grivas, N.; Liew, M.; Linares Espinós, E.E.; Oldenburg, J.; Oprea-Lager, D.E.; Ploussard, G.; Rouvière, O.; Schoots, I.G.; Smith, E.J.; Stranne, J.; Smith, C.T.; Van Den Bergh, R.C.N.; Van Oort, I.M.; Wiegel, T.; Yuan, C.Y.; Van den Broeck, T.; Henry, A.M., Koç University Hospital, School of Medicine, Tilki, Derya, Slevin, F.; Zattoni, F.; Checcucci, E.; Cumberbatch, M.G.K.; Nacchia, A.; Cornford, P.; Briers, E.; De Meerleer, G.; De Santis, M.; Eberli, D.; Gandaglia, G.; Gillessen, S.; Grivas, N.; Liew, M.; Linares Espinós, E.E.; Oldenburg, J.; Oprea-Lager, D.E.; Ploussard, G.; Rouvière, O.; Schoots, I.G.; Smith, E.J.; Stranne, J.; Smith, C.T.; Van Den Bergh, R.C.N.; Van Oort, I.M.; Wiegel, T.; Yuan, C.Y.; Van den Broeck, T.; Henry, A.M., Koç University Hospital, and School of Medicine
- Abstract
Background Central nervous system (CNS) prophylactic options for diffuse large B-cell lymphoma (DLBCL) are administered differently in most centers. Unfortunately, there is still not a consensus on which patients, which regimen, for how many cycles, and when prophy-laxis should be administered. Thus, this remains an unmet clinical need. Methods We administered a survey study under the Lymphoma Scientific Subcommittee of the Turkish Society of Haematology. The questions were directed to hematologists through the monkey survey system. Results The CNS International Prognostic Index score is a factor that clinicians frequently use when deciding on prophylaxis and is considered reliable. Although the perspective on anatomical risk factors is similar to that reported in the literature, breast involvement is still considered a critical risk factor in Turkey. Participants considered double or triple hit and double/triple expressor lymphoma as significant risk factors. Various methods have been used to demonstrate CNS relapses. Intrathecal prophylaxis is the preferred method. Conclusion There are diverse methodological and technical ideas. The controversial results reported in the literature on the effectiveness of CNS prophylaxis may explain this finding. Although CNS prophylactic methods for patients with DLBCL are still controversial, the effect of secondary CNS involvement on survival is inevitable. Standard practices followed by na-tional guidelines may be effective in reducing the variety of application methods and creat-ing homogeneous results for efficacy and survival follow-up studies., NA
- Published
- 2023
6. Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review.
- Author
-
Marra, G., Leenders, G.J.L.H. van, Zattoni, F., Kesch, C., Rajwa, P., Cornford, P., Kwast, T. van der, Bergh, R.C.N. van den, Briers, E., Broeck, T. Van den, Meerleer, G. de, Santis, M. de, Eberli, D., Farolfi, A., Gillessen, S., Grivas, N., Grummet, J.P., Henry, A.M., Lardas, M., Lieuw, M., Linares Espinós, E., Mason, M.D., O'Hanlon, S., Oort, I.M. van, Oprea-Lager, D.E., Ploussard, G., Rouvière, O., Schoots, I.G., Stranne, J., Tilki, D., Wiegel, T., Willemse, P.M., Mottet, N., Gandaglia, G., Marra, G., Leenders, G.J.L.H. van, Zattoni, F., Kesch, C., Rajwa, P., Cornford, P., Kwast, T. van der, Bergh, R.C.N. van den, Briers, E., Broeck, T. Van den, Meerleer, G. de, Santis, M. de, Eberli, D., Farolfi, A., Gillessen, S., Grivas, N., Grummet, J.P., Henry, A.M., Lardas, M., Lieuw, M., Linares Espinós, E., Mason, M.D., O'Hanlon, S., Oort, I.M. van, Oprea-Lager, D.E., Ploussard, G., Rouvière, O., Schoots, I.G., Stranne, J., Tilki, D., Wiegel, T., Willemse, P.M., Mottet, N., and Gandaglia, G.
- Abstract
01 juli 2023, Item does not contain fulltext, CONTEXT: The optimal management for men with prostate cancer (PCa) with unconventional histology (UH) is unknown. The outcome for these cancers might be worse than for conventional PCa and so different approaches may be needed. OBJECTIVE: To compare oncological outcomes for conventional and UH PCa in men with localized disease treated with curative intent. EVIDENCE ACQUISITION: A systematic review adhering to the Referred Reporting Items for Systematic Reviews and Meta-Analyses was prospectively registered on PROSPERO (CRD42022296013) was performed in July 2021. EVIDENCE SYNTHESIS: We screened 3651 manuscripts and identified 46 eligible studies (reporting on 1 871 814 men with conventional PCa and 6929 men with 10 different PCa UHs). Extraprostatic extension and lymph node metastases, but not positive margin rates, were more common with UH PCa than with conventional tumors. PCa cases with cribriform pattern, intraductal carcinoma, or ductal adenocarcinoma had higher rates of biochemical recurrence and metastases after radical prostatectomy than for conventional PCa cases. Lower cancer-specific survival rates were observed for mixed cribriform/intraductal and cribriform PCa. By contrast, pathological findings and oncological outcomes for mucinous and prostatic intraepithelial neoplasia (PIN)-like PCa were similar to those for conventional PCa. Limitations of this review include low-quality studies, a risk of reporting bias, and a scarcity of studies that included radiotherapy. CONCLUSIONS: Intraductal, cribriform, and ductal UHs may have worse oncological outcomes than for conventional and mucinous or PIN-like PCa. Alternative treatment approaches need to be evaluated in men with these cancers. PATIENT SUMMARY: We reviewed the literature to explore whether prostate cancers with unconventional growth patterns behave differently to conventional prostate cancers. We found that some unconventional growth patterns have worse outcomes, so we need to investigate if they nee
- Published
- 2023
7. Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304–6: Prebiopsy MRI: Through the Looking Glass
- Author
-
van den Bergh R. C. N., Rouviere O., van der Kwast T., Briers E., Van den Broeck T., Cornford P., Cumberbatch M. G., De Santis M., Fanti S., Fossati N., Gandaglia G., Grivas N., Grummet J., Lam T. B., Lardas M., Liew M., Moris L., Mason M. D., Mottet N., Oprea-Lager D. E., Ploussard G., Schoots I. G., Tilki D., van der Poel H. G., Wiegel T., Willemse P. -P. M., van den Bergh, R. C. N., Rouviere, O., van der Kwast, T., Briers, E., Van den Broeck, T., Cornford, P., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Grivas, N., Grummet, J., Lam, T. B., Lardas, M., Liew, M., Moris, L., Mason, M. D., Mottet, N., Oprea-Lager, D. E., Ploussard, G., Schoots, I. G., Tilki, D., van der Poel, H. G., Wiegel, T., and Willemse, P. -P. M.
- Subjects
Male ,Humans ,Prostatic Neoplasms ,Magnetic Resonance Imaging - Published
- 2020
8. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer
- Author
-
Beyer, K., MacLennan, S.J., Moris, L., Lardas, M., Mastris, K., Hooker, G., Greene, R., Briers, E., Omar, M.I., Healey, J., Tripathee, S., Gandaglia, G., Venderbos, L.D.F., Smith, E.J., Bjorkqvist, J., Asiimwe, A., Huber, J., Roobol, M.J., Zong, J., Bjartell, A., N'Dow, J., Briganti, A., Schalken, J.A., MacLennan, S., Hemelrijck, M. Van, Beyer, K., MacLennan, S.J., Moris, L., Lardas, M., Mastris, K., Hooker, G., Greene, R., Briers, E., Omar, M.I., Healey, J., Tripathee, S., Gandaglia, G., Venderbos, L.D.F., Smith, E.J., Bjorkqvist, J., Asiimwe, A., Huber, J., Roobol, M.J., Zong, J., Bjartell, A., N'Dow, J., Briganti, A., Schalken, J.A., MacLennan, S., and Hemelrijck, M. Van
- Abstract
Contains fulltext : 244306.pdf (Publisher’s version ) (Open Access), Patients are the stewards of their own care and hence their voice is important when designing and implementing research. Patients should be involved not only as participants in research that impacts their care, as the recipients of that care and any associated harms, but also as research collaborators in prioritising important questions from the patient perspective and designing the research and the ways in which is it most appropriate to involve patients. The PIONEER Consortium, an international multistakeholder collaboration lead by the European Association of Urology, has developed a core outcome set (COS) for localised and metastatic prostate cancer relevant to all stakeholders in particular patients. Throughout the work of PIONEER, patient representatives were involved as collaborators in setting the research agenda, and a wider group of patients was involved as participants in developing COSs, for instance in consensus meetings on choosing important outcomes and appropriate definitions. This publication showcases the process for COS development and highlights the most important recommendations to ultimately inform future research projects co-created between patients and other stakeholders. PATIENT SUMMARY: An important step in involving patients in the selection of outcomes for clinical trials, clinical audits, and real-world evidence is the development of a core outcome set (COS) that is relevant to all stakeholders. This report highlights the patient participation throughout our PIONEER COS development. TAKE HOME MESSAGE: An important step in involving patients in the selection of outcomes for clinical trials, clinical audits, and real-world evidence is to develop a core outcome set (COS) that is relevant to all stakeholders. As part of the work of the PIONEER Consortium, we aim to highlight the patient participation throughout our PIONEER COS development.
- Published
- 2021
9. Evaluation of oncological outcomes and data quality in studies assessing nerve sparing versus non-nerve sparing radical prostatectomy in non-metastatic prostate cancer: A systematic review
- Author
-
Moris, L., primary, Gandaglia, G., additional, Vilaseca, A., additional, Van Den Broeck, T., additional, Briers, E., additional, De Santis, M., additional, Gillessen, S., additional, Grivas, N., additional, Henry, A., additional, Lam, T.B., additional, Lardas, M., additional, Mason, M., additional, Oprea-Lager, D., additional, Ploussard, G., additional, Rouvière, O., additional, Schoots, I.G., additional, Van Der Poel, H., additional, Wiegel, T., additional, Willemse, P-P., additional, Grummet, J.P., additional, Tilke, D., additional, Van Den Bergh, R.C.N., additional, Cornford, P., additional, and Mottet, N., additional
- Published
- 2021
- Full Text
- View/download PDF
10. A systematic review on the impact of surgeon and hospital caseload volume on oncological and non-oncological outcomes after radical prostatectomy for non-metastatic prostate cancer
- Author
-
Van Den Broeck, T., primary, Oprea-Lager, D., additional, Moris, L., additional, Kailavasan, M., additional, Briers, E., additional, Cornford, P., additional, De Santis, M., additional, Gandaglia, G., additional, Gillessen Sommer, S., additional, Grummet, J.P., additional, Grivas, N., additional, Lam, T.B., additional, Lardas, M., additional, Liew, M., additional, Mason, M., additional, O’Hanlon, S., additional, Ploussard, G., additional, Rouvière, O., additional, Schoots, I., additional, Tilki, D., additional, Van Den Bergh, R.C.N., additional, Van Der Poel, H., additional, Wiegel, T., additional, Willemse, P., additional, and Mottet, N., additional
- Published
- 2021
- Full Text
- View/download PDF
11. Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.016: Prebiopsy MRI: Through the Looking Glass
- Author
-
Bergh, R.C.N. (Roderick) van den, Rouvière, O. (Olivier), Kwast, Th.H. (Theo) van der, Briers, E. (Erik), van den Broeck, T. (Thomas), Cornford, P. (Philip), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fanti, S. (Stefano), Fossati, N. (Nicola), Gandaglia, G. (Giorgio), Grivas, N. (Nikolaos), Grummet, J. (Jeremy), Lam, T.B. (Thomas B.), Lardas, M. (Michael), Liew, M. (Matthew), Moris, L. (Lisa), Mason, M.D. (Malcolm), Mottet, N. (Nicolas), Oprea-Lager, D.E. (Daniela E.), Ploussard, G. (Guillaume), Schoots, I.G. (Ivo), Tilki, D. (Derya), Poel, H.G. (Henk) van der, Wiegel, T. (Thomas), Willemse, P.-P.M. (Peter-Paul M.), Bergh, R.C.N. (Roderick) van den, Rouvière, O. (Olivier), Kwast, Th.H. (Theo) van der, Briers, E. (Erik), van den Broeck, T. (Thomas), Cornford, P. (Philip), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fanti, S. (Stefano), Fossati, N. (Nicola), Gandaglia, G. (Giorgio), Grivas, N. (Nikolaos), Grummet, J. (Jeremy), Lam, T.B. (Thomas B.), Lardas, M. (Michael), Liew, M. (Matthew), Moris, L. (Lisa), Mason, M.D. (Malcolm), Mottet, N. (Nicolas), Oprea-Lager, D.E. (Daniela E.), Ploussard, G. (Guillaume), Schoots, I.G. (Ivo), Tilki, D. (Derya), Poel, H.G. (Henk) van der, Wiegel, T. (Thomas), and Willemse, P.-P.M. (Peter-Paul M.)
- Published
- 2020
- Full Text
- View/download PDF
12. 'TREXIT 2020': why the time to abandon transrectal prostate biopsy starts now
- Author
-
Grummet, J, Gorin, MA, Popert, R, O'Brien, T, Lamb, AD, Hadaschik, B, Radtke, JP, Wagenlehner, F, Baco, E, Moore, CM, Emberton, M, George, AK, Davis, JW, Szabo, RJ, Buckley, R, Loblaw, A, Allaway, M, Kastner, C, Briers, E, Royce, PL, Frydenberg, M, Murphy, DG, Woo, HH, Grummet, J, Gorin, MA, Popert, R, O'Brien, T, Lamb, AD, Hadaschik, B, Radtke, JP, Wagenlehner, F, Baco, E, Moore, CM, Emberton, M, George, AK, Davis, JW, Szabo, RJ, Buckley, R, Loblaw, A, Allaway, M, Kastner, C, Briers, E, Royce, PL, Frydenberg, M, Murphy, DG, and Woo, HH
- Published
- 2020
13. PT348 - Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A systematic review
- Author
-
Van Den Broeck, T., Van Den Bergh, R.C.N., Arfi, N., Gross, T., Moris, L., Briers, E., Cumberbatch, M.G.K., De Santis, M., Tilki, D., Fanti, S., Fossati, N., Gillessen Sommer, S., Grummet, J., Henry, A., Lardas, M., Liew, M., Rouvière, O., Pecanka, J., Mason, M., Schoots, I.G., Van der Kwast, T., Van Der Poel, H.G., Wiegel, T., Willemse, P-P.M., Yuan, Y., Lam, T.B., Cornford, P., and Mottet, N.
- Published
- 2019
- Full Text
- View/download PDF
14. The EAU biochemical recurrence risk stratification after radical prostatectomy
- Author
-
Van Den Broeck, T., primary, Van Den Bergh, R.C.N., additional, Arfi, N., additional, Gross, T., additional, Moris, L., additional, Briers, E., additional, Markus, C., additional, Maria, D.S., additional, Fanti, S., additional, Fossati, N., additional, Gillessen, S., additional, Grummet, J.P., additional, Henry, A.M., additional, Lardas, M., additional, Rouvière, O., additional, Mason, M.D., additional, Schoots, I., additional, Van Der Kwast, T., additional, Van Der Poel, H.G., additional, Wiegel, T., additional, Willemse, P.M., additional, Lam, T.B., additional, Cornford, P., additional, Mottet, N., additional, and Tilki, D., additional
- Published
- 2020
- Full Text
- View/download PDF
15. Current treatment options for locally advanced prostate cancer: EAU (-SIOG) guidelines view and recommendations
- Author
-
Moris, L., primary, Cumberbatch, M.C., additional, Van Den Broeck, T., additional, Gandaglia, G., additional, Fossati, N., additional, Briers, E., additional, Cornford, P., additional, De Santis, M., additional, Fanti, S., additional, Gillessen, S., additional, Grummet, J., additional, Henry, A.M., additional, Lam, T.B.L., additional, Lardas, M., additional, Liew, M., additional, Mason, M.D., additional, Rouvière, O., additional, Tilki, D., additional, Schoots, I.G., additional, Van Den Bergh, R.C.N., additional, Van Der Kwast, T.H., additional, Van Der Poel, H.G, additional, Willemse, P.M., additional, Mottet, N., additional, and Wiegel, T., additional
- Published
- 2020
- Full Text
- View/download PDF
16. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
- Author
-
Lam, T.B., MacLennan, S., Willemse, P.M., Mason, M.D., Plass, K., Shepherd, R., Baanders, R., Bangma, Chris H., Bjartell, A., Bossi, A., Briers, E., Briganti, A., Buddingh, K.T., Catto, J.W., Colecchia, M., Cox, B.W., Cumberbatch, M.G.K., Davies, J., Davis, N.F., De Santis, M., Dell'Oglio, P., Deschamps, A., Donaldson, J.F., Egawa, S., Fankhauser, C.D., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., Grivas, N., Gross, T., Grummet, J.P., Henry, A.M., Ingels, A., Irani, J., Lardas, M., Liew, M., Lin, D.W., Moris, L., Omar, M.I., Pang, K.H., Paterson, C.C., Renard-Penna, R., Ribal, M.J., Roobol, M.J., Roupret, M., Rouviere, O., Sancho Pardo, G., Richenberg, J., Schoots, I.G., Sedelaar, J.P.M., Stricker, P., Tilki, D., Vahr Lauridsen, S., van den Bergh, R.C.N., Van den Broeck, T., van der Kwast, T.H., van der Poel, H.G., van Leenders, G., Varma, M., Violette, P.D., Wallis, C.J.D., Wiegel, T., Wilkinson, K., Zattoni, F., N'Dow, J.M.O., Van Poppel, H., Cornford, P., Mottet, N., Lam, T.B., MacLennan, S., Willemse, P.M., Mason, M.D., Plass, K., Shepherd, R., Baanders, R., Bangma, Chris H., Bjartell, A., Bossi, A., Briers, E., Briganti, A., Buddingh, K.T., Catto, J.W., Colecchia, M., Cox, B.W., Cumberbatch, M.G.K., Davies, J., Davis, N.F., De Santis, M., Dell'Oglio, P., Deschamps, A., Donaldson, J.F., Egawa, S., Fankhauser, C.D., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., Grivas, N., Gross, T., Grummet, J.P., Henry, A.M., Ingels, A., Irani, J., Lardas, M., Liew, M., Lin, D.W., Moris, L., Omar, M.I., Pang, K.H., Paterson, C.C., Renard-Penna, R., Ribal, M.J., Roobol, M.J., Roupret, M., Rouviere, O., Sancho Pardo, G., Richenberg, J., Schoots, I.G., Sedelaar, J.P.M., Stricker, P., Tilki, D., Vahr Lauridsen, S., van den Bergh, R.C.N., Van den Broeck, T., van der Kwast, T.H., van der Poel, H.G., van Leenders, G., Varma, M., Violette, P.D., Wallis, C.J.D., Wiegel, T., Wilkinson, K., Zattoni, F., N'Dow, J.M.O., Van Poppel, H., Cornford, P., and Mottet, N.
- Abstract
Contains fulltext : 215783.pdf (publisher's version ) (Closed access), BACKGROUND: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. OBJECTIVE: To develop consensus statements for all domains of DAT. DESIGN, SETTING, AND PARTICIPANTS: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. RESULTS AND LIMITATIONS: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. CONCLUSIONS: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. PATIENT
- Published
- 2019
17. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A systematic review
- Author
-
Van Den Broeck, T., primary, Van Den Bergh, R.C.N., additional, Arfi, N., additional, Gross, T., additional, Moris, L., additional, Briers, E., additional, Cumberbatch, M.G.K., additional, De Santis, M., additional, Tilki, D., additional, Fanti, S., additional, Fossati, N., additional, Gillessen Sommer, S., additional, Grummet, J., additional, Henry, A., additional, Lardas, M., additional, Liew, M., additional, Rouvière, O., additional, Pecanka, J., additional, Mason, M., additional, Schoots, I.G., additional, Van der Kwast, T., additional, Van Der Poel, H.G., additional, Wiegel, T., additional, Willemse, P-P.M., additional, Yuan, Y., additional, Lam, T.B., additional, Cornford, P., additional, and Mottet, N., additional
- Published
- 2019
- Full Text
- View/download PDF
18. Systematic review of quality of life outcomes after primary treatment for clinically localised prostate cancer
- Author
-
Lardas, M., primary, Liew, M., additional, Van Den Bergh, R.C., additional, De Santis, M., additional, Bellmunt, J., additional, Van Den Broeck, T., additional, Cornford, P., additional, Cumberbatch, M.G., additional, Fossati, N., additional, Gross, T., additional, Henry, A.M., additional, Bolla, M., additional, Briers, E., additional, Joniau, S., additional, Lam, T.B., additional, Mason, M.D., additional, Mottet, N., additional, Van Der Poel, H.G., additional, Rouvière, O., additional, Schoots, I.G., additional, Wiegel, T., additional, Willemse, P.P.M., additional, Yuan, C.Y., additional, and Bourke, L., additional
- Published
- 2018
- Full Text
- View/download PDF
19. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis
- Author
-
Moldovan, P., primary, Van Den Broeck, T., additional, Sylvester, R., additional, Marconi, L., additional, Bellmunt, J., additional, Van Den Bergh, R.C.N., additional, Bolla, M., additional, Briers, E., additional, Cumberbatch, M.G., additional, Fossati, N., additional, Gross, T., additional, Henry, A.M., additional, Joniau, S., additional, Van Der Kwast, T.H., additional, Matveev, V.B., additional, Van Der Poel, H.G., additional, De Santis, M., additional, Schoots, I.G., additional, Wiegel, T., additional, Yuan, C.Y., additional, Cornford, P., additional, Mottet, N., additional, Lam, T.B., additional, and Rouvière, O., additional
- Published
- 2018
- Full Text
- View/download PDF
20. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: A systematic review
- Author
-
Fossati, N., primary, Willemse, P.-P., additional, Van Den Broeck, T., additional, Yuan, Y., additional, Briers, E., additional, Bellmunt, J., additional, Bolla, M., additional, Cornford, P., additional, De Santis, M., additional, MacPepple, E., additional, Henry, A.M., additional, Matveev, S., additional, Van Der Poel, H.G., additional, Van Der Kwast, T., additional, Rouvière, O., additional, Wiegel, T., additional, Lam, T., additional, Mottet, N., additional, and Joniau, S., additional
- Published
- 2018
- Full Text
- View/download PDF
21. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- Author
-
Mottet, N. (Nicolas), Bellmunt, J. (Joaquim), Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Lam, T.B. (Thomas B.), Mason, M.D. (Malcolm), Matveev, V. (Vsevolod), Moldovan, P.C. (Paul C.), Bergh, R.C.N. (Roderick) van den, van den Broeck, T. (Thomas), Poel, H.G. (Henk) van der, Kwast, Th.H. (Theo) van der, Rouvière, O. (Olivier), Schoots, I.G. (Ivo), Wiegel, T. (Thomas), Cornford, P. (Philip), Mottet, N. (Nicolas), Bellmunt, J. (Joaquim), Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Lam, T.B. (Thomas B.), Mason, M.D. (Malcolm), Matveev, V. (Vsevolod), Moldovan, P.C. (Paul C.), Bergh, R.C.N. (Roderick) van den, van den Broeck, T. (Thomas), Poel, H.G. (Henk) van der, Kwast, Th.H. (Theo) van der, Rouvière, O. (Olivier), Schoots, I.G. (Ivo), Wiegel, T. (Thomas), and Cornford, P. (Philip)
- Abstract
Objective: To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). Evidence acquisition: The working panel performed a literature review of the new data (2013-2015). The guidelines were updated and the levels of evidence and/or grades of recommendation were added based on a systematic review of the evidence. Evidence synthesis: . BRCA2 mutations have been added as risk factors for early and aggressive disease. In addition to the Gleason score, the five-tier 2014 International Society of Urological Pathology grading system should now be provided. Systematic screening is still not recommended. Instead, an individual risk-adapted strategy following a detailed discussion and taking into account the patient's wishes and life expectancy must be considered. An early prostate-specific antigen test, the use of a risk calculator, or one of the promising biomarker tools are being investigated and might be able to limit the overdetection of insignificant PCa. Breaking the link between diagnosis and treatment may lower the overtreatment risk. Multiparametric magnetic resonance imaging
- Published
- 2017
- Full Text
- View/download PDF
22. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy?
- Author
-
Moldovan, P.C. (Paul C.), van den Broeck, T. (Thomas), Sylvester, R. (Richard), Marconi, L. (Lorenzo), Bellmunt, J. (Joaquim), Bergh, R.C.N. (Roderick) van den, Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Kwast, Th.H. (Theo) van der, Matveev, V. (Vsevolod), Poel, H.G. (Henk) van der, Santis, M. (Maria) de, Schoots, I.G. (Ivo), Wiegel, T. (Thomas), Yuan, C.Y. (Cathy Yuhong), Cornford, P. (Philip), Mottet, N. (Nicolas), Lam, T.B. (Thomas B.), Rouvière, O. (Olivier), Moldovan, P.C. (Paul C.), van den Broeck, T. (Thomas), Sylvester, R. (Richard), Marconi, L. (Lorenzo), Bellmunt, J. (Joaquim), Bergh, R.C.N. (Roderick) van den, Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Kwast, Th.H. (Theo) van der, Matveev, V. (Vsevolod), Poel, H.G. (Henk) van der, Santis, M. (Maria) de, Schoots, I.G. (Ivo), Wiegel, T. (Thomas), Yuan, C.Y. (Cathy Yuhong), Cornford, P. (Philip), Mottet, N. (Nicolas), Lam, T.B. (Thomas B.), and Rouvière, O. (Olivier)
- Abstract
Context: It remains unclear whether patients with a suspicion of prostate cancer (PCa) and negative multiparametric magnetic resonance imaging (mpMRI) can safely obviate prostate biopsy. Objective: To systematically review the literature assessing the negative predictive value (NPV) of mpMRI in patients with a suspicion of PCa. Evidence acquisition: The Embase, Medline, and Cochrane databases were searched up to February 2016. Studies reporting prebiopsy mpMRI results using transrectal or transperineal biopsy as a reference standard were included. We further selected for meta-analysis studies with at least 10-core biopsies as the reference standard, mpMRI comprising at least T2-weighted and diffusion-weighted imaging, positive mpMRI defined as a Prostate Imaging Reporting Data System/Likert score of ≥3/5 or ≥4/5, and results reported at patient level for the detection of overall PCa or clinically significant PCa (csPCa) defined as Gleason ≥7 cancer. Evidence synthesis: A total of 48 studies (9613 patients) were eligible for inclusion. At patient level, the median prevalence was 50.4% (interquartile range [IQR], 36.4-57.7%) for overall cancer and 32.9% (IQR, 28.1-37.2%) for csPCa. The median mpMRI NPV was 82.4% (IQR, 69.0-92.4%) for overall cancer and 88.1% (IQR, 85.7-92.3) for csPCa. NPV significantly decreased when cancer prevalence increased, for overall cancer (r = -0.64, p <. 0.0001) and csPCa (r = -0.75, p = 0.032). Eight studies fulfilled the inclusion criteria for meta-analysis. Seven reported results for overall PCa. When the overall PCa prevalence increased from 30% to 60%, the combined NPV estimates decreased from 88% (95% confidence interval [95% CI], 77-99%) to 67% (95% CI, 56-79%) for a cut-off score of 3/5. Only one study selected for meta-analysis reported results for Gleason ≥7 cancers, with a positive biopsy rate of 29.3%. The corresponding NPV for a cut-off score of ≥3/5 was 87.9%. Conclusions: The NPV of mpMRI varied greatly depending on study des
- Published
- 2017
- Full Text
- View/download PDF
23. EP-1419: Optimal design and patient selection for interventional trials using radiogenomic biomarkers
- Author
-
De Ruysscher, D., primary, Defraene, G., additional, Ramaekers, B., additional, Lambin, P., additional, Briers, E., additional, Stobart, H., additional, Ward, T., additional, Bentzen, S., additional, Van Staa, T., additional, Kerns, S., additional, and West, C., additional
- Published
- 2017
- Full Text
- View/download PDF
24. How can cancer treatment remain affordable?
- Author
-
Annemans, L., Bauwens, S., Beyers, S., Briers, E., Bulens, F., Bulens, P., and Remmen, Roy
- Subjects
Human medicine - Published
- 2014
25. PT009 - The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: A systematic review
- Author
-
Fossati, N., Willemse, P.-P., Van Den Broeck, T., Yuan, Y., Briers, E., Bellmunt, J., Bolla, M., Cornford, P., De Santis, M., MacPepple, E., Henry, A.M., Matveev, S., Van Der Poel, H.G., Van Der Kwast, T., Rouvière, O., Wiegel, T., Lam, T., Mottet, N., and Joniau, S.
- Published
- 2018
- Full Text
- View/download PDF
26. PT008 - What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis
- Author
-
Moldovan, P., Van Den Broeck, T., Sylvester, R., Marconi, L., Bellmunt, J., Van Den Bergh, R.C.N., Bolla, M., Briers, E., Cumberbatch, M.G., Fossati, N., Gross, T., Henry, A.M., Joniau, S., Van Der Kwast, T.H., Matveev, V.B., Van Der Poel, H.G., De Santis, M., Schoots, I.G., Wiegel, T., Yuan, C.Y., Cornford, P., Mottet, N., Lam, T.B., and Rouvière, O.
- Published
- 2018
- Full Text
- View/download PDF
27. PT010 - Systematic review of quality of life outcomes after primary treatment for clinically localised prostate cancer
- Author
-
Lardas, M., Liew, M., Van Den Bergh, R.C., De Santis, M., Bellmunt, J., Van Den Broeck, T., Cornford, P., Cumberbatch, M.G., Fossati, N., Gross, T., Henry, A.M., Bolla, M., Briers, E., Joniau, S., Lam, T.B., Mason, M.D., Mottet, N., Van Der Poel, H.G., Rouvière, O., Schoots, I.G., Wiegel, T., Willemse, P.P.M., Yuan, C.Y., and Bourke, L.
- Published
- 2018
- Full Text
- View/download PDF
28. Policy statement on multidisciplinary cancer care
- Author
-
Borras, Jm, Albreht, T, Audisio, R, Briers, E, Casali, P, Esperou, H, Grube, B, Hamoir, M, Henning, G, Kelly, J, Knox, S, Nabal, M, Pierotti, M, Lombardo, C, Van Harten, W, Poston, G, Prades, J, Sant, M, Travado, L, Valentini, Vincenzo, Van De Velde, C, Van Den Bogaert, S, Van Den Bulcke, M, Van Hoof, E, Van Den Neucker, I, Wilson, R., Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Borras, Jm, Albreht, T, Audisio, R, Briers, E, Casali, P, Esperou, H, Grube, B, Hamoir, M, Henning, G, Kelly, J, Knox, S, Nabal, M, Pierotti, M, Lombardo, C, Van Harten, W, Poston, G, Prades, J, Sant, M, Travado, L, Valentini, Vincenzo, Van De Velde, C, Van Den Bogaert, S, Van Den Bulcke, M, Van Hoof, E, Van Den Neucker, I, Wilson, R., and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
- Abstract
Cancer care is undergoing an important paradigm shift from a disease-focused management to a patient-centred approach, in which increasingly more attention is paid to psychosocial aspects, quality of life, patients' rights and empowerment and survivorship. In this context, multidisciplinary teams emerge as a practical necessity for optimal coordination among health professionals and clear communication with patients. The European Partnership for Action Against Cancer (EPAAC), an initiative launched by the European Commission in 2009, addressed the multidisciplinary care from a policy perspective in order to define the core elements that all tumour-based multidisciplinary teams (MDTs) should include. To that effect, a working group conference was held in January 2013 within the EPAAC Work Package 7 (on Healthcare) framework.
- Published
- 2014
29. 244 INVITED Prostate Cancer Patients – What do They Really Need?
- Author
-
Denis, L., primary, Briers, E., additional, Boeye, F., additional, Van Daele, H., additional, Dourcy-Belle-Rose, B., additional, and Costa, A., additional
- Published
- 2011
- Full Text
- View/download PDF
30. A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research
- Author
-
Ann Henry, Stefano Fanti, Nicolas Mottet, Olivier Rouvière, Thomas Lumsden, Theodorus H. van der Kwast, Thomas Van den Broeck, Nicola Fossati, Nikolaos A. Kostakopoulos, Malcolm David Mason, Daniela E. Oprea-Lager, Thomas B. Lam, Philip Cornford, Erik Briers, Henk G. van der Poel, Thomas Wiegel, Guillaume Ploussard, Peter-Paul M. Willemse, Giorgio Gandaglia, Anthony Simon Bates, Marcus G. Cumberbatch, Silke Gillessen, Derya Tilki, Ivo G. Schoots, Jeremy Grummet, Michael Lardas, Roderick C.N. van den Bergh, Maria De Santis, Lisa Moris, Matthew Liew, Jennifer Ayers, James N'Dow, Yuhong Yuan, Bates, A. S., Ayers, J., Kostakopoulos, N., Lumsden, T., Schoots, I. G., Willemse, P. -P. M., Yuan, Y., van den Bergh, R. C. N., Grummet, J. P., van der Poel, H. G., Rouviere, O., Moris, L., Cumberbatch, M. G., Lardas, M., Liew, M., Van den Broeck, T., Gandaglia, G., Fossati, N., Briers, E., De Santis, M., Fanti, S., Gillessen, S., Oprea-Lager, D. E., Ploussard, G., Henry, A. M., Tilki, D., van der Kwast, T. H., Wiegel, T., N'Dow, J., Mason, M. D., Cornford, P., Mottet, N., Lam, T. B. L., and Bates AS, Ayers J, Kostakopoulos N, Lumsden T, Schoots IG, Willemse PM, Yuan Y, van den Bergh RCN, Grummet JP, van der Poel HG, Rouvière O, Moris L, Cumberbatch MG, Lardas M, Liew M, Van den Broeck T, Gandaglia G, Fossati N, Briers E, De Santis M, Fanti S, Gillessen S, Oprea-Lager DE, Ploussard G, Henry AM, Tilki D, van der Kwast TH, Wiegel T, N'Dow J, Mason MD, Cornford P, Mottet N, Lam TBL.
- Subjects
Male ,Radical treatment ,medicine.medical_specialty ,Localised prostate cancer ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Context (language use) ,law.invention ,External validity ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Randomized controlled trial ,law ,Internal medicine ,Clinical practice guidelines and recommendations ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,External beam radiotherapy ,Limitations of evidence base ,Prospective cohort study ,Prostatectomy ,Clinical practice, Systematic review, Localised prostate cancer ,business.industry ,Prostate ,Prostatic Neoplasms ,Retrospective cohort study ,Clinical trial ,Treatment Outcome ,Oncology ,Evidence synthesis ,030220 oncology & carcinogenesis ,Systematic review ,Quality of Life ,Oncological and functional outcomes ,Surgery ,business ,Focal ablative therapy - Abstract
Context The clinical effectiveness of focal therapy (FT) for localised prostate cancer (PCa) remains controversial. Objective To analyse the evidence base for primary FT for localised PCa via a systematic review (SR) to formulate clinical practice recommendations. Evidence acquisition A protocol-driven, PRISMA-adhering SR comparing primary FT (sub-total, focal, hemi-gland, or partial ablation) versus standard options (active surveillance [AS], radical prostatectomy [RP], or external beam radiotherapy [EBRT]) was undertaken. Only comparative studies with ≥50 patients per arm were included. Primary outcomes included oncological, functional, and quality-of-life outcomes. Risk of bias (RoB) and confounding assessments were undertaken. Eligible SRs were reviewed and appraised (AMSTAR) and ongoing prospective comparative studies were summarised. Evidence synthesis Out of 1119 articles identified, four primary studies (1 randomised controlled trial [RCT] and 3 retrospective studies) recruiting 3961 patients and ten eligible SRs were identified. Only qualitative synthesis was possible owing to clinical heterogeneity. Overall, RoB and confounding were moderate to high. An RCT comparing vascular-targeted focal photodynamic therapy (PDT) with AS found a significantly lower rate of treatment failure at 2 yr with PDT. There were no differences in functional outcomes, although PDT was associated with worse transient adverse events. However, the external validity of the study was contentious. A retrospective study comparing focal HIFU with robotic RP found no significant differences in treatment failure at 3 yr, with focal HIFU having better continence and erectile function recovery. Two retrospective cohort studies using Surveillance, Epidemiology and End Results data compared focal laser ablation (FLA) against RP and EBRT, reporting significantly worse oncological outcomes for FLA. The overall data quality and applicability of the primary studies were limited because of clinical heterogeneity, RoB and confounding, lack of long-term data, inappropriate outcome measures, and poor external validity. Virtually all the SRs identified concluded that there was insufficient high-certainty evidence to make definitive conclusions regarding the clinical effectiveness of FT, with the majority of SRs judged to have a low or critically low confidence rating. Eight ongoing prospective comparative studies were identified. Ways of improving the evidence base are discussed. Conclusions The certainty of the evidence regarding the comparative effectiveness of FT as a primary treatment for localised PCa was low, with significant uncertainties. Until higher-certainty evidence emerges from robust prospective comparative studies measuring clinically meaningful outcomes at long-term time points, FT should ideally be performed within clinical trials or well-designed prospective cohort studies. Patient summary We examined the literature to determine the effectiveness of prostate-targeted treatment compared with standard treatments for untreated localised prostate cancer. There was no strong evidence showing that focal treatment compares favourably with standard treatments; consequently, focal treatment is not recommended for routine standard practice.
- Published
- 2021
- Full Text
- View/download PDF
31. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- Author
-
Thomas Van den Broeck, Philip Cornford, Michael Lardas, Nicola Fossati, Stefano Fanti, Ann Henry, Erik Briers, Thomas Wiegel, Marcus G. Cumberbatch, Nicolas Mottet, Olivier Rouvière, Roderick C.N. van den Bergh, Silke Gillessen, Ivo G. Schoots, Theodorus H. van der Kwast, Peter-Paul M. Willemse, Giorgio Gandaglia, Maria De Santis, Derya Tilki, N. Grivas, Lisa Moris, Matthew Liew, Malcolm David Mason, Henk G. van der Poel, Daniela E. Oprea-Lager, Jeremy Grummet, Thomas B. Lam, Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., Grivas, N., Grummet, J., Henry, A. M., van der Kwast, T. H., Lam, T. B., Lardas, M., Liew, M., Mason, M. D., Moris, L., Oprea-Lager, D. E., van der Poel, H. G., Rouviere, O., Schoots, I. G., Tilki, D., Wiegel, T., Willemse, P. -P. M., Cornford, P., Pathology, Radiology & Nuclear Medicine, and Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P.
- Subjects
Male ,Quality of life ,medicine.medical_specialty ,Staging ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Active surveillance ,Scientific evidence ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Breast cancer ,SDG 3 - Good Health and Well-being ,Biopsy ,Diagnosis ,medicine ,Humans ,Prostate cancer, EAU-EANM-ESTRO-ESUR-SIOG ,EAU-EANM-ESTRO-ESUR-SIOG guidelines ,Intensive care medicine ,Early Detection of Cancer ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,medicine.disease ,Radical prostatectomy ,Radiation therapy ,Treatment ,Localised ,Geriatric oncology ,030220 oncology & carcinogenesis ,Life expectancy ,Screening ,Androgen deprivation ,business - Abstract
Objective: To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa). Evidence acquisition: The panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence. Evidence synthesis: A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment. Conclusions: The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management. Patient summary: Updated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. The 2020 European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on prostate cancer (PCa) summarise the most recent findings and provide recommendations for clinical practice, addressing screening, diagnosis, and local treatment with curative intent. Key stakeholders in PCa management were involved in their development, including a patient representative. A full version is available at the EAU office and online at http://uroweb.org/guideline/prostate-cancer/. A separate publication will address the management of relapsing-, metastatic-, and castration-resistant PCa.
- Published
- 2021
- Full Text
- View/download PDF
32. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
- Author
-
Nicolas Mottet, Lisa Moris, Maria De Santis, Thomas B. Lam, Matthew Liew, Giorgio Gandaglia, Theodorus H. van der Kwast, Nikolaos Grivas, Silke Gillessen, Thomas Van den Broeck, Ann Henry, Philip Cornford, Michael Lardas, Marcus G. Cumberbatch, Nicola Fossati, Erik Briers, Malcolm David Mason, Daniela E. Oprea-Lager, Jeremy Grummet, Thomas Wiegel, Henk G. van der Poel, Ivo G. Schoots, Stefano Fanti, Roderick C.N. van den Bergh, Peter-Paul M. Willemse, Derya Tilki, Olivier Rouvière, Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., Grivas, N., Grummet, J., Henry, A. M., der Kwast, T. H. V., Lam, T. B., Lardas, M., Liew, M., Mason, M. D., Moris, L., Oprea-Lager, D. E., der Poel, H. G. V., Rouviere, O., Schoots, I. G., Tilki, D., Wiegel, T., Willemse, P. -P. M., Mottet, N., and Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Mottet N.
- Subjects
Biochemical recurrence ,Oncology ,Quality of life ,Male ,medicine.medical_specialty ,Castration resistant ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,urologic and male genital diseases ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Palliative, Prostate cancer, Follow-up ,Internal medicine ,medicine ,Chemotherapy ,Humans ,EAU-EANM-ESTRO-ESUR-SIOG guidelines ,Relapse ,Neoplasm Metastasis ,Palliative ,Prostatectomy ,business.industry ,Follow-up ,Prostatic Neoplasms ,Evidence-based medicine ,Guideline ,medicine.disease ,Radiation therapy ,Geriatric oncology ,030220 oncology & carcinogenesis ,Hormonal therapy ,Metastatic ,Neoplasm Recurrence, Local ,business - Abstract
Objective: To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). Evidence acquisition: The working panel performed a literature review of the new data (2016–2019). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature. Evidence synthesis: Prostate-specific membrane antigen positron emission tomography computed tomography scanning has developed an increasingly important role in men with biochemical recurrence after local therapy. Early salvage radiotherapy after radical prostatectomy appears as effective as adjuvant radiotherapy and, in a subset of patients, should be combined with androgen deprivation. New treatments have become available for men with metastatic hormone-sensitive prostate cancer (PCa), nonmetastatic CRPC, and metastatic CRPC, along with a role for local radiotherapy in men with low-volume metastatic hormone-sensitive PCa. Also included is information on quality of life outcomes in men with PCa. Conclusions: The knowledge in the field of advanced and metastatic PCa and CRPC is changing rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are first endorsed by the EANM and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/). Patient summary: This article summarises the guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are evidence based and guide the clinician in the discussion with the patient on the treatment decisions to be taken. These guidelines are updated every year; this summary spans the 2017–2020 period of new evidence. The knowledge in the field of advanced and metastatic prostate cancer (PCa) and castration-resistant prostate cancer is changing rapidly. The 2020 European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are first endorsed by the EANM and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/).
- Published
- 2020
33. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
- Author
-
Maria De Santis, Suneil Jain, Nicolas Mottet, Philip Cornford, Henk G. van der Poel, Peter Paul M. Willemse, Olivier Rouvière, Theodorus H. van der Kwast, Malcolm David Mason, Muhammad Imran Omar, Raj P. Pal, Silke Gillessen, Nicola Fossati, Brian D. Kelly, Marcus G. Cumberbatch, Derya Tilki, Tanya B. Dorff, Stefano Fanti, Thomas Van den Broeck, Erik Briers, Ivo G. Schoots, Michael Lardas, Lisa Moris, Thomas Wiegel, Matthew Liew, Roderick C.N. van den Bergh, Badrinath R. Konety, Thomas B. Lam, Ann Henry, Jeremy Grummet, Cathy Yuhong Yuan, Giorgio Gandaglia, Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, Pal R, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet JP, Henry AM, Lam TBL, Lardas M, Liew M, Mason MD, Omar MI, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, van Der Kwast TH, van Der Poel HG, Willemse PM, Yuan CY, Konety B, Dorff T, Jain S, Mottet N, Wiegel T., Moris, L., Cumberbatch, M. G., Van den Broeck, T., Gandaglia, G., Fossati, N., Kelly, B., Pal, R., Briers, E., Cornford, P., De Santis, M., Fanti, S., Gillessen, S., Grummet, J. P., Henry, A. M., Lam, T. B. L., Lardas, M., Liew, M., Mason, M. D., Omar, M. I., Rouviere, O., Schoots, I. G., Tilki, D., van den Bergh, R. C. N., van Der Kwast, T. H., van Der Poel, H. G., Willemse, P. -P. M., Yuan, C. Y., Konety, B., Dorff, T., Jain, S., Mottet, N., Wiegel, T., Radiology & Nuclear Medicine, and Pathology
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Internationality ,medicine.medical_treatment ,Urology ,Brachytherapy ,030232 urology & nephrology ,Locally advanced ,External beam radiotherapy ,Systemic treatment ,Review ,Modality treatment ,Risk Assessment ,Primary therapy ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Multidisciplinary approach ,Internal medicine ,medicine ,Journal Article ,Humans ,Neoplasm Metastasis ,Intensive care medicine ,Neoplasm Staging ,business.industry ,Prostatic Neoplasms ,Androgen Antagonists ,Localized ,medicine.disease ,Radical prostatectomy ,030220 oncology & carcinogenesis ,Systematic review ,business - Abstract
Context: The optimal treatment for men with high-risk localized or locally advanced prostate cancer (PCa) remains unknown. Objective: To perform a systematic review of the existing literature on the effectiveness of the different primary treatment modalities for high-risk localized and locally advanced PCa. The primary oncological outcome is the development of distant metastases at ≥5 yr of follow-up. Secondary oncological outcomes are PCa-specific mortality, overall mortality, biochemical recurrence, and need for salvage treatment with ≥5 yr of follow-up. Nononcological outcomes are quality of life (QoL), functional outcomes, and treatment-related side effects reported. Evidence acquisition: Medline, Medline In-Process, Embase, and the Cochrane Central Register of Randomized Controlled Trials were searched. All comparative (randomized and nonrandomized) studies published between January 2000 and May 2019 with at least 50 participants in each arm were included. Studies reporting on high-risk localized PCa (International Society of Urologic Pathologists [ISUP] grade 4-5 [Gleason score {GS} 8-10] or prostate-specific antigen [PSA] >20 ng/ml or ≥ cT2c) and/or locally advanced PCa (any PSA, cT3-4 or cN+, any ISUP grade/GS) or where subanalyses were performed on either group were included. The following primary local treatments were mandated: radical prostatectomy (RP), external beam radiotherapy (EBRT) (≥64 Gy), brachytherapy (BT), or multimodality treatment combining any of the local treatments above (±any systemic treatment). Risk of bias (RoB) and confounding factors were assessed for each study. A narrative synthesis was performed. Evidence synthesis: Overall, 90 studies met the inclusion criteria. RoB and confounding factors revealed high RoB for selection, performance, and detection bias, and low RoB for correction of initial PSA and biopsy GS. When comparing RP with EBRT, retrospective series suggested an advantage for RP, although with a low level of evidence. Both RT and RP should be seen as part of a multimodal treatment plan with possible addition of (postoperative) RT and/or androgen deprivation therapy (ADT), respectively. High levels of evidence exist for EBRT treatment, with several randomized clinical trials showing superior outcome for adding long-term ADT or BT to EBRT. No clear cutoff can be proposed for RT dose, but higher RT doses by means of dose escalation schemes result in an improved biochemical control. Twenty studies reported data on QoL, with RP resulting mainly in genitourinary toxicity and sexual dysfunction, and EBRT in bowel problems. Conclusions: Based on the results of this systematic review, both RP as part of multimodal treatment and EBRT + long-term ADT can be recommended as primary treatment in high-risk and locally advanced PCa. For high-risk PCa, EBRT + BT can also be offered despite more grade 3 toxicity. Interestingly, for selected patients, for example, those with higher comorbidity, a shorter duration of ADT might be an option. For locally advanced PCa, EBRT + BT shows promising result but still needs further validation. In this setting, it is important that patients are aware that the offered therapy will most likely be in the context a multimodality treatment plan. In particular, if radiation is used, the combination of local with systemic treatment provides the best outcome, provided the patient is fit enough to receive both. Until the results of the SPCG15 trial are known, the optimal local treatment remains a matter of debate. Patients should at all times be fully informed about all available options, and the likelihood of a multimodal approach including the potential side effects of both local and systemic treatment. Patient summary: We reviewed the literature to see whether the evidence from clinical studies would tell us the best way of curing men with aggressive prostate cancer that had not spread to other parts of the body such as lymph glands or bones. Based on the results of this systematic review, there is good evidence that both surgery and radiation therapy are good treatment options, in terms of prolonging life and preserving quality of life, provided they are combined with other treatments. In the case of surgery this means including radiotherapy (RT), and in the case of RT this means either hormonal therapy or combined RT and brachytherapy.
- Published
- 2020
- Full Text
- View/download PDF
34. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
- Author
-
Niall F. Davis, Muhammad Imran Omar, Alberto Briganti, Olivier Rouvière, James N'Dow, Ann Henry, Brett Cox, James W.F. Catto, Derya Tilki, Christopher J.D. Wallis, Maurizio Colecchia, Silke Gillessen, Steven MacLennan, Murali Varma, Thomas Van den Broeck, Philip Cornford, Susanne Vahr Lauridsen, J.P. Michiel Sedelaar, Nicola Fossati, Michael Lardas, Gemma Sancho Pardo, Paolo Dell'Oglio, André Deschamps, Nicolas Mottet, Lisa Moris, Marcus G. Cumberbatch, Thomas Wiegel, Raphaële Renard-Penna, Fabio Zattoni, James Donaldson, Phillip D. Stricker, Matthew Liew, Ivo G. Schoots, Stefano Fanti, Theodorus H. van der Kwast, Geert J.L.H. van Leenders, Nikolaos Grivas, Monique J. Roobol, Erik Briers, Hendrik Van Poppel, Karin Plass, Jeff Davies, Jonathan Richenberg, Maria De Santis, Jacques Irani, Daniel W. Lin, Shin Egawa, Tobias Gross, Peter Paul M. Willemse, Roderick C.N. van den Bergh, Alberto Bossi, Henk G. van der Poel, Chris H. Bangma, Maria J. Ribal, Giorgio Gandaglia, Alexandre Ingels, Karl H. Pang, Morgan Rouprêt, Robert Shepherd, Jeremy Grummet, Thomas B. Lam, Malcolm David Mason, Catherine Paterson, Karel Tim Buddingh, Christian D. Fankhauser, Ruud Baanders, Anders Bjartell, Philippe D. Violette, Karen Wilkinson, Lam, T. B. L., Maclennan, S., Willemse, P. -P. M., Mason, M. D., Plass, K., Shepherd, R., Baanders, R., Bangma, C. H., Bjartell, A., Bossi, A., Briers, E., Briganti, A., Buddingh, K. T., Catto, J. W. F., Colecchia, M., Cox, B. W., Cumberbatch, M. G., Davies, J., Davis, N. F., De Santis, M., Dell'Oglio, P., Deschamps, A., Donaldson, J. F., Egawa, S., Fankhauser, C. D., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., Grivas, N., Gross, T., Grummet, J. P., Henry, A. M., Ingels, A., Irani, J., Lardas, M., Liew, M., Lin, D. W., Moris, L., Omar, M. I., Pang, K. H., Paterson, C. C., Renard-Penna, R., Ribal, M. J., Roobol, M. J., Roupret, M., Rouviere, O., Sancho Pardo, G., Richenberg, J., Schoots, I. G., Sedelaar, J. P. M., Stricker, P., Tilki, D., Vahr Lauridsen, S., van den Bergh, R. C. N., Van den Broeck, T., van der Kwast, T. H., van der Poel, H. G., van Leenders, G. J. L. H., Varma, M., Violette, P. D., Wallis, C. J. D., Wiegel, T., Wilkinson, K., Zattoni, F., N'Dow, J. M. O., Van Poppel, H., Cornford, P., Mottet, N., Urology, Radiology & Nuclear Medicine, Pathology, and Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Colecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N.
- Subjects
Male ,medicine.medical_specialty ,Localised prostate cancer ,Urology ,education ,030232 urology & nephrology ,Delphi method ,Reclassification ,Outcome measures ,Time-to-Treatment ,Outcome measure ,03 medical and health sciences ,Prostate cancer ,Active surveillance and monitoring ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Consensus group meeting ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,medicine ,Humans ,610 Medicine & health ,Clinical practice guideline ,Curative intent ,Clinical Oncology ,Eligibility ,business.industry ,Follow-up ,Prostatic Neoplasms ,Consensus statements ,Guideline ,Deferred treatment with curative intent ,medicine.disease ,Clinical practice guidelines ,Delphi survey ,Deferred treatment ,Consensus statement ,030220 oncology & carcinogenesis ,Family medicine ,business - Abstract
Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers. (C) 2019 Published by Elsevier B.V. on behalf of European Association of Urology.
- Published
- 2019
35. A0666 - Why is there a need to re-think prostate cancer early detection?
- Author
-
Beyer, K., Leenen, R., Venderbos, L.D.F., Denijs, F., Helleman, J., Chloupkova, R., Májek, O., Briers, E., Vasilyeva, V., Gomez Rivas, J., Annemans, L., Vynckier, P., Basu, P., Chandran, A., Van Den Bergh, R.C.N., Collen, S., Stenzl, A., Van Poppel, H., and Roobol, M.J.
- Subjects
- *
EARLY detection of cancer , *PROSTATE cancer - Published
- 2024
- Full Text
- View/download PDF
36. A0665 - Understanding the barriers to prostate cancer population-based early detection programs: The PRAISE-U BEST survey.
- Author
-
Beyer, K., Leenen, R., Venderbos, L.D.F., Helleman, J., Denijs, F., Gomez Rivas, J., Vasilyeva, V., Briers, E., Chloupkova, R., Májek, O., Frese, T., Vilaseca, J., Vinker, S., Vynckier, P., Annemans, L., Basu, P., Chandran, A., Van Den Bergh, R.C.N., Collen, S., and Van Poppel, H.
- Subjects
- *
EARLY detection of cancer , *PROSTATE cancer - Published
- 2024
- Full Text
- View/download PDF
37. Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer
- Author
-
Thomas P. A. Debray, Christopher Berridge, Thomas Van den Broeck, Cathy Yuhong Yuan, Silke Gillessen, Nicola Fossati, Fabio Zattoni, Malcolm David Mason, Thomas B. Lam, Giorgio Gandaglia, Ann Henry, Olivier Rouvière, Marcus G. Cumberbatch, Guillaume Ploussard, Shane O'Hanlon, Thomas Wiegel, Philip Cornford, Henk G. van der Poel, Andrea Farolfi, Lisa Moris, Jeremy Grummet, Matthew Liew, N. Grivas, Daniela E. Oprea-Lager, Michael Lardas, Ivo G. Schoots, Erik Briers, Maria De Santis, Nicolas Mottet, Theodorus H. van der Kwast, Derya Tilki, Peter-Paul M. Willemse, Roderick C.N. van den Bergh, Lardas, M., Grivas, N., Debray, T. P. A., Zattoni, F., Berridge, C., Cumberbatch, M., Van den Broeck, T., Briers, E., De Santis, M., Farolfi, A., Fossati, N., Gandaglia, G., Gillessen, S., O'Hanlon, S., Henry, A., Liew, M., Mason, M., Moris, L., Oprea-Lager, D., Ploussard, G., Rouviere, O., Schoots, I. G., van der Kwast, T., van der Poel, H., Wiegel, T., Willemse, P. -P., Yuan, C. Y., Grummet, J. P., Tilki, D., van den Bergh, R. C. N., Lam, T. B., Cornford, P., and Mottet, N.
- Subjects
Male ,medicine.medical_specialty ,Evidence synthesis ,Patient-related factors ,Prognostic factors ,Prostate cancer ,Systematic review ,Tumour-related factors ,Urinary incontinence ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Context (language use) ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,medicine ,Humans ,Prospective Studies ,Randomized Controlled Trials as Topic ,Retrospective Studies ,Prostatectomy ,business.industry ,Confounding ,Prostate ,Prostatic Neoplasms ,Odds ratio ,Prognosis ,medicine.disease ,Urinary Incontinence ,Urethra ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Meta-analysis ,medicine.symptom ,business - Abstract
Context While urinary incontinence (UI) commonly occurs after radical prostatectomy (RP), it is unclear what factors increase the risk of UI development. Objective To perform a systematic review of patient- and tumour-related prognostic factors for post-RP UI. The primary outcome was UI within 3 mo after RP. Secondary outcomes included UI at 3–12 mo and ≥12 mo after RP. Evidence acquisition Databases including Medline, EMBASE, and CENTRAL were searched between January 1990 and May 2020. All studies reporting patient- and tumour-related prognostic factors in univariable or multivariable analyses were included. Surgical factors were excluded. Risk of bias (RoB) and confounding assessments were performed using the Quality In Prognosis Studies (QUIPS) tool. Random-effects meta-analyses were performed for all prognostic factor, where possible. Evidence synthesis A total of 119 studies (5 randomised controlled trials, 24 prospective, 88 retrospective, and 2 case-control studies) with 131 379 patients were included. RoB was high for study participation and confounding; moderate to high for statistical analysis, study attrition, and prognostic factor measurement; and low for outcome measurements. Significant prognostic factors for postoperative UI within 3 mo after RP were age (odds ratio [OR] per yearly increase 1.04, 95% confidence interval [CI] 1.03–1.05), membranous urethral length (MUL; OR per 1-mm increase 0.81, 95% CI 0.74–0.88), prostate volume (PV; OR per 1-ml increase 1.005, 95% CI 1.000–1.011), and Charlson comorbidity index (CCI; OR 1.28, 95% CI 1.09–1.50). Conclusions Increasing age, shorter MUL, greater PV, and higher CCI are independent prognostic factors for UI within 3 mo after RP, with all except CCI remaining prognostic at 3–12 mo. Patient summary We reviewed the literature to identify patient and disease factors associated with urinary incontinence after surgery for prostate cancer. We found increasing age, larger prostate volume, shorter length of a section of the urethra (membranous urethra), and lower fitness were associated with worse urinary incontinence for the first 3 mo after surgery, with all except lower fitness remaining predictive at 3–12 mo.
- Published
- 2022
- Full Text
- View/download PDF
38. A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer
- Author
-
N. Grivas, Guillaume Ploussard, Peter-Paul M. Willemse, Jakub Pecanka, Roderick C.N. van den Bergh, Maria De Santis, Thomas Van den Broeck, Nicolas Mottet, Thomas Wiegel, Olivier Rouvière, Jeremy Grummet, Silke Gillessen Sommer, Mithun Kailavasan, Daniela E. Oprea-Lager, Michael Lardas, Shane O'Hanlon, Cathy Yuhong Yuan, Henk G. van der Poel, Thomas B. Lam, Giorgio Gandaglia, Lisa Moris, Matthew Liew, Derya Tilki, Philip Cornford, Erik Briers, Ivo G. Schoots, Malcolm David Mason, Van den Broeck, T., Oprea-Lager, D., Moris, L., Kailavasan, M., Briers, E., Cornford, P., De Santis, M., Gandaglia, G., Gillessen Sommer, S., Grummet, J. P., Grivas, N., Lam, T. B. L., Lardas, M., Liew, M., Mason, M., O'Hanlon, S., Pecanka, J., Ploussard, G., Rouviere, O., Schoots, I. G., Tilki, D., van den Bergh, R. C. N., van der Poel, H., Wiegel, T., Willemse, P. -P., Yuan, C. Y., and Mottet, N.
- Subjects
Male ,Biochemical recurrence ,medicine.medical_specialty ,Blood transfusion ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,MEDLINE ,Context (language use) ,Workload ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Interquartile range ,Outcome Assessment, Health Care ,Oncological outcomes ,Humans ,Medicine ,Prostatectomy ,Surgeons ,Surgeon volume ,business.industry ,General surgery ,Prostate ,Prostatic Neoplasms ,Perioperative ,medicine.disease ,Functional outcomes ,Hospitals ,Hospital volume ,Treatment Outcome ,Evidence synthesis ,030220 oncology & carcinogenesis ,Systematic review ,Neoplasm Recurrence, Local ,business ,Delivery of Health Care ,Hospitals, High-Volume - Abstract
Context The impact of surgeon and hospital volume on outcomes after radical prostatectomy (RP) for localised prostate cancer (PCa) remains unknown. Objective To perform a systematic review on the association between surgeon or hospital volume and oncological and nononcological outcomes following RP for PCa. Evidence acquisition Medline, Medline In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched. All comparative studies for nonmetastatic PCa patients treated with RP published between January 1990 and May 2020 were included. For inclusion, studies had to compare hospital or surgeon volume, defined as caseload per unit time. Main outcomes included oncological (including prostate-specific antigen persistence, positive surgical margin [PSM], biochemical recurrence, local and distant recurrence, and cancer-specific and overall survival) and nononcological (perioperative complications including need for blood transfusion, conversion to open procedure and within 90-d death, and continence and erectile function) outcomes. Risk of bias (RoB) and confounding assessments were undertaken. Both a narrative and a quantitative synthesis were planned if the data allowed. Evidence synthesis Sixty retrospective comparative studies were included. Generally, increasing surgeon and hospital volumes were associated with lower rates of mortality, PSM, adjuvant or salvage therapies, and perioperative complications. Combining group size cut-offs as used in the included studies, the median threshold for hospital volume at which outcomes start to diverge is 86 (interquartile range [IQR] 35–100) cases per year. In addition, above this threshold, the higher the caseload, the better the outcomes, especially for PSM. RoB and confounding were high for most domains. Conclusions Higher surgeon and hospital volumes for RP are associated with lower rates of PSMs, adjuvant or salvage therapies, and perioperative complications. This association becomes apparent from a caseload of >86 (IQR 35–100) per year and may further improve hereafter. Both high- and low-volume centres should measure their outcomes, make them publicly available, and improve their quality of care if needed. Patient summary We reviewed the literature to determine whether the number of prostate cancer operations (radical prostatectomy) performed in a hospital affects the outcomes of surgery. We found that, overall, hospitals with a higher number of operations per year have better outcomes in terms of cancer recurrence and complications during or after hospitalisation. However, it must be noted that surgeons working in hospitals with lower annual operations can still achieve similar or even better outcomes. Therefore, making hospital’s outcome data publicly available should be promoted internationally, so that patients can make an informed decision where they want to be treated.
- Published
- 2021
- Full Text
- View/download PDF
39. Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non–Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review
- Author
-
Michael Lardas, Maria De Santis, Erik Briers, Giorgio Gandaglia, Thomas B. Lam, Shane O'Hanlon, Silke Gillessen, Peter-Paul M. Willemse, Nicolas Mottet, Cathy Yuhong Yuan, Thomas Van den Broeck, Guillaume Ploussard, Roderick C.N. van den Bergh, Olivier Rouvière, Ivo G. Schoots, Thomas Wiegel, Antoni Vilaseca, Malcolm David Mason, Henk G. van der Poel, Ann Henry, Derya Tilki, N. Grivas, Daniela E. Oprea-Lager, Jeremy Grummet, Philip Cornford, Lisa Moris, Moris, L., Gandaglia, G., Vilaseca, A., Van den Broeck, T., Briers, E., De Santis, M., Gillessen, S., Grivas, N., O'Hanlon, S., Henry, A., Lam, T. B., Lardas, M., Mason, M., Oprea-Lager, D., Ploussard, G., Rouviere, O., Schoots, I. G., van der Poel, H., Wiegel, T., Willemse, P. -P., Yuan, C. Y., Grummet, J. P., Tilki, D., van den Bergh, R. C. N., Cornford, P., and Mottet, N.
- Subjects
Biochemical recurrence ,Oncology ,Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Subgroup analysis ,Context (language use) ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Internal medicine ,Medicine ,Humans ,Prospective Studies ,Prostatectomy ,Positive surgical margins ,business.industry ,Prostate ,Cancer ,Margins of Excision ,Prostatic Neoplasms ,medicine.disease ,Neurovascular bundle ,Data Accuracy ,Nerve-sparing radical prostatectomy ,Evidence synthesis ,030220 oncology & carcinogenesis ,Systematic review ,business ,Cohort study ,Oncological outcome - Abstract
Context Surgical techniques aimed at preserving the neurovascular bundles during radical prostatectomy (RP) have been proposed to improve functional outcomes. However, it remains unclear if nerve-sparing (NS) surgery adversely affects oncological metrics. Objective To explore the oncological safety of NS versus non-NS (NNS) surgery and to identify factors affecting the oncological outcomes of NS surgery. Evidence acquisition Relevant databases were searched for English language articles published between January 1, 1990 and May 8, 2020. Comparative studies for patients with nonmetastatic prostate cancer (PCa) treated with primary RP were included. NS and NNS techniques were compared. The main outcomes were side-specific positive surgical margins (ssPSM) and biochemical recurrence (BCR). Risk of bias (RoB) and confounding assessments were performed. Evidence synthesis Out of 1573 articles identified, 18 studies recruiting a total of 21 654 patients were included. The overall RoB and confounding were high across all domains. The most common selection criteria for NS RP identified were characteristic of low-risk disease, including low core-biopsy involvement. Seven studies evaluated the link with ssPSM and showed an increase in ssPSM after adjustment for side-specific confounders, with the relative risk for NS RP ranging from 1.50 to 1.53. Thirteen papers assessing BCR showed no difference in outcomes with at least 12 mo of follow-up. Lack of data prevented any subgroup analysis for potentially important variables. The definitions of NS were heterogeneous and poorly described in most studies. Conclusions Current data revealed an association between NS surgery and an increase in the risk of ssPSM. This did not translate into a negative impact on BCR, although follow-up was short and many men harbored low-risk PCa. There are significant knowledge gaps in terms of how various patient, disease, and surgical factors affect outcomes. Adequately powered and well-designed prospective trials and cohort studies accounting for these issues with long-term follow-up are recommended. Patient summary Neurovascular bundles (NVBs) are structures containing nerves and blood vessels. The NVBs close to the prostate are responsible for erections. We reviewed the literature to determine if a technique to preserve the NVBs during removal of the prostate causes worse cancer outcomes. We found that NVB preservation was poorly defined but, if applied, was associated with a higher risk of cancer at the margins of the tissue removed, even in patients with low-risk prostate cancer. The long-term importance of this finding for patients is unclear. More data are needed to provide recommendations.
- Published
- 2021
- Full Text
- View/download PDF
40. Biochemical Recurrence in Prostate Cancer : The European Association of Urology Prostate Cancer Guidelines Panel Recommendations
- Author
-
Ann Henry, Nicolas Mottet, Malcolm David Mason, Thomas Wiegel, Michael Lardas, Derya Tilki, Ivo G. Schoots, Theodorus H. van der Kwast, Olivier Rouvière, Henk G. van der Poel, Silke Gillessen, Jeremy Grummet, Peter Paul M. Willemse, Nicola Fossati, Thomas Van den Broeck, Lisa Moris, Philip Cornford, Matthew Liew, Thomas B. Lam, Marcus G. Cumberbatch, Maria De Santis, Erik Briers, Roderick C.N. van den Bergh, Stefano Fanti, Radiology & Nuclear Medicine, Pathology, and Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Mason M, Moris L, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PM, Rouvière O, Lam TB, Mottet N.
- Subjects
Male ,Biochemical recurrence ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,PSA kinetic ,030232 urology & nephrology ,Disease ,Guideline ,Guidelines ,Prognostic factors ,Risk Assessment ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Radiotherapy ,SDG 3 - Good Health and Well-being ,medicine ,Journal Article ,Humans ,Blood test ,Gleason score ,Patient summary ,Prognostic factor ,medicine.diagnostic_test ,business.industry ,breakpoint cluster region ,Prostatic Neoplasms ,Prostate-Specific Antigen ,medicine.disease ,Radical prostatectomy ,Radiation therapy ,European Association of Urology ,PSA kinetics ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Neoplasm Recurrence, Local ,business ,Progressive disease - Abstract
Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.
- Published
- 2020
41. Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer
- Author
-
Nicola Fossati, Karel Tim Buddingh, Malcolm David Mason, Karin Plass, Christian D. Fankhauser, Steven MacLennan, Michael Lardas, James N'Dow, Henk G. van der Poel, Hendrik Van Poppel, Thomas B. Lam, Philip Cornford, Thomas Van den Broeck, Alexandre Ingels, Thomas Wiegel, Niall F. Davis, Peter-Paul M. Willemse, Catherine Paterson, Olivier Rouvière, Silke Gillessen, Lisa Moris, Fabio Zattoni, Marcus G. Cumberbatch, Matthew Liew, Theodorus H. van der Kwast, Ivo G. Schoots, Jeremy Grummet, Tobias Gross, N. Grivas, Stefano Fanti, Roderick C.N. van den Bergh, Ann Henry, Paolo Dell'Oglio, N. Mottet, James Donaldson, Muhammad Imran Omar, Derya Tilki, Maria De Santis, Erik Briers, Karl H. Pang, Radiology & Nuclear Medicine, Pathology, and Lam TBL, MacLennan S, Plass K, Willemse PM, Mason MD, Cornford P, Donaldson J, Davis NF, Dell'Oglio P, Fankhauser C, Grivas N, Ingels A, Lardas M, Liew M, Pang KH, Paterson C, Omar MI, Zattoni F, Buddingh KT, Van den Broeck T, Cumberbatch MG, Fossati N, Gross T, Moris L, Schoots IG, van den Bergh RCN, Briers E, Fanti S, De Santis M, Gillessen S, Grummet JP, Henry AM, van der Poel HG, van der Kwast TH, Rouvière O, Tilki D, Wiegel T, N'Dow J, Van Poppel H, Mottet N.
- Subjects
Research design ,Male ,medicine.medical_specialty ,Consensus ,Letter ,Delphi Technique ,Consensus Development Conferences as Topic ,Urology ,education ,030232 urology & nephrology ,Delphi method ,MEDLINE ,Prostatic Neoplasms/pathology ,Evidence-Based Medicine ,Humans ,Medical Oncology ,Multicenter Studies as Topic ,Prostatic Neoplasms ,Systematic Reviews as Topic ,Treatment Outcome ,Research Design ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,medicine ,610 Medicine & health ,computer.programming_language ,Protocol (science) ,business.industry ,Prostate Cancer ,Urology/standards ,Stakeholder ,Evidence-based medicine ,Guideline ,030220 oncology & carcinogenesis ,Family medicine ,Medical Oncology/standards ,business ,computer ,Delphi ,Multicenter Studies as Topic/methods - Abstract
Deferred active treatment (DAT) strategies, including active surveillance and active monitoring, are a recognised management option for men with localised low-risk prostate cancer. However, there is uncertainty due to heterogeneity of patient selection criteria, follow-up and monitoring characteristics, reclassification thresholds, and which outcome measures should be prioritised. This protocol describes a study led by the European Association of Urology (EAU) Prostate Cancer Guidelines Panel in conjunction with other guideline organisations and societies to develop consensus statements for all domains of deferred active treatment. The project is divided into 3 sequential phases: (1) Systematic review of studies reporting on DAT in order to summarise and define range of heterogeneity regarding all domains; (2) Two-round Delphi online survey involving a large, international panel of healthcare professionals (HCPs) and patients to initiate consensus; and (3) Consensus group meeting involving representatives from HCP and patient stakeholder groups to finalise the consensus process. The consensus statements are expected to be adopted by clinical practice guidelines in order to standardise and guide practice for clinicians and researchers until better evidence emerges. Patient summary: We describe a project aimed at standardising elements of practice in active surveillance/monitoring for early localised prostate cancer, because currently there is great variation and uncertainty regarding how best to conduct them. This will be achieved through a structured process of agreement (i.e. consensus) amongst a large, international panel of healthcare professionals and patients.
- Published
- 2019
42. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
- Author
-
Vynckier P, Annemans L, Raes S, Amrouch C, Lindgren P, Májek O, Beyer K, Leenen RCA, Venderbos LDF, Denijs F, van Harten MJ, Helleman J, Chloupková R, Briers E, Vasilyeva V, Rivas JG, Basu P, Chandran A, van den Bergh RCN, Collen S, Van Poppel H, and Roobol MJ
- Subjects
- Humans, Male, Europe, Prostate-Specific Antigen blood, Quality-Adjusted Life Years, Magnetic Resonance Imaging economics, Health Care Costs, Aged, Middle Aged, Mass Screening economics, Mass Screening methods, Cost-Effectiveness Analysis, Prostatic Neoplasms diagnosis, Prostatic Neoplasms economics, Cost-Benefit Analysis, Early Detection of Cancer economics, Early Detection of Cancer methods
- Abstract
Background and Objective: In Europe, prostate cancer (PCa) is the most common cancer in men. Screening may therefore be crucial to lower health care costs, morbidity, and mortality. This systematic review aimed to provide a contemporary overview of the costs and benefits of PCa screening programmes., Methods: A peer-reviewed literature search was conducted, using the PICO method. A detailed search strategy was developed in four databases based on the following key search terms: "PCa", "screening", and "cost effectiveness". Any type of economic evaluation was included. The search strategy was restricted to European countries, but no restrictions were set on the year of publication., Key Findings and Limitations: A total of 7484 studies were identified initially. Of these, 19 studies described the cost effectiveness of PCa screening in Europe. Among the studies using an initially healthy study population, most focussed on risk- and/or age- and/or magnetic resonance imaging (MRI)-based screening in addition to prostate-specific antigen (PSA) testing and compared this with no screening. Incremental cost ratios (ICERs) varied from €5872 per quality-adjusted life year (QALY) to €372 948/QALY, with a median of €56 487/QALY. Risk-based screening followed by MRI testing seemed to be a more cost-effective strategy than no screening., Conclusions and Clinical Implications: This systematic review indicates that screening programmes incorporating a risk-based approach and MRI have the potential to be cost effective., Patient Summary: In this review, we looked at the cost effectiveness of prostate cancer screening in Europe. We found that a risk-based approach and incorporation of magnetic resonance imaging has the potential to be cost effective. However, there remains a knowledge gap regarding cost effectiveness of prostate cancer screening. Therefore, determinants of cost effectiveness require further investigation., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
43. Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.
- Author
-
Aziz MK, Molony D, Monlezun D, Holder T, Brunckhorst O, Higgason N, Roland J, Magill R, Fatakdawala M, Iacobucci A, Mody-Bailey N, Owen C, Zarker A, Thames E, Swaby J, Xiao D, Choi L, Desai S, Galan J, Deng B, Hartshorne T, Nichols A, Zhang A, Imber J, Song J, Jones W, Rivas A, Sanchez D, Guhan M, Gandaglia G, Ranganath S, Jacob J, Howell S, Plana J, van den Bergh R, Roberts M, Sommer SG, Oldenburg J, Ploussard G, Tilki D, Schoots I, Briers E, Stranne J, Rouviere O, van Oort I, Oprea-Lager D, De Santis M, and Cornford P
- Abstract
Background and Objective: Recommendations of first-line therapies for metastatic hormone-sensitive (mHSPC), nonmetastatic castrate-resistant (M0CRPC), and metastatic castrate-resistant (mCRPC) prostate cancer do not account for cardiotoxicity due to a lack of clear prior evidence. This manuscript assesses cardiotoxicity of these therapies., Methods: We searched Ovid Medline, Elsevier Embase, and the Cochrane Library for randomized clinical trials (RCTs) from database inception to January 14, 2024. Network meta-analyses of first-line mHSPC, M0CRPC, and mCRPC therapies were constructed for the five cardiotoxicity metrics defined by the International Cardio-Oncology Society: heart failure, myocarditis, vascular toxicity, hypertension, and arrhythmias. Additional Bayesian network meta-analyses also accounted for prior treatment history., Key Findings and Limitations: Thirteen RCTs (16 292 patients) were included. For mHSPC, androgen deprivation therapy (ADT) plus docetaxel (DTX) plus abiraterone acetate (AA) with prednisone (P) demonstrated a significant increase in hypertension and arrhythmias versus ADT + DTX (risk ratio [RR] 2.85, 95% confidence interval [CI] 1.67-4.89, and RR 2.01, 95% CI 1.17-3.44, respectively); however, no corresponding differences were observed between ADT + DTX plus darolutamide (DAR) and ADT + DTX (RR 1.55, 95% CI 0.73-3.30, and RR 0.94, 95% CI 0.63-1.40, respectively). For mCRPC assuming a history of mHSPC treatment, ADT + AA + P plus olaparib (OLA) demonstrated a statistically significant decrease in hypertension versus ADT + AA + P (RR 0.20, 95% CI 0.16-0.26). M0CRPC results were unremarkable., Conclusions and Clinical Implications: For mHSPC, ADT + DTX + DAR demonstrates less cardiotoxicity than ADT + DTX + AA + P due to a lower risk of hypertension and arrhythmias from decreased mineralocorticoid excess. In addition, OLA counterintuitively offers decreased hypertension when superimposed on ADT + AA + P for mCRPC treatment after prior androgen deprivation from mHSPC therapy., (Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Prostate Cancer Early Detection in the European Union and UK.
- Author
-
Leenen RCA, Venderbos LDF, Helleman J, Gómez Rivas J, Vynckier P, Annemans L, Chloupková R, Májek O, Briers E, Vasilyeva V, Remmers S, van Harten MJ, Denijs FB, de Vos II, Chandran A, Basu P, van den Bergh RCN, Collen S, Van Poppel H, Roobol MJ, and Beyer K
- Abstract
Background and Objective: While prostate cancer (PCa) incidence and mortality rates continue to rise, early detection of PCa remains highly controversial, and the research landscape is rapidly evolving. Existing systematic reviews (SRs) and meta-analyses (MAs) provide valuable insights, but often focus on single aspects of early detection, hindering a comprehensive understanding of the topic. We aim to fill this gap by providing a comprehensive SR of contemporary SRs covering different aspects of early detection of PCa in the European Union (EU) and the UK., Methods: On June 1, 2023, we searched four databases (Medline ALL via Ovid, Embase, Web of Science, and Cochrane Central Register of Controlled Trials) and Google Scholar. To avoid repetition of previous studies, only SRs (qualitative, quantitative, and/or MAs) were considered eligible. In the data, common themes were identified to present the evidence systematically., Key Findings and Limitations: We identified 1358 citations, resulting in 26 SRs eligible for inclusion. Six themes were identified: (1) invitation: men at general risk should be invited at >50 yr of age, and testing should be discontinued at >70 yr or with <10 yr of life expectancy; (2) decision-making: most health authorities discourage population-based screening and instead recommend a shared decision-making (SDM) approach, but implementation of SDM in clinical practice varies widely; decision aids help men make more informed and value-consistent screening decisions and decrease men's intention to attempt screening, but these do not affect screening uptake; (3) acceptance: facilitators for men considering screening include social prompting by partners and clinician recommendations, while barriers include a lack of knowledge, low-risk perception, and masculinity attributes; (4) screening test and algorithm: prostate-specific antigen-based screening reduces PCa-specific mortality and metastatic disease in men aged 55-69 yr at randomisation if screened at least twice; (5) harms and benefits: these benefits come at the cost of unnecessary biopsies, overdiagnosis, and subsequent overtreatment; and (6) future of screening: risk-adapted screening including (prebiopsy) risk calculators, magnetic resonance imaging, and blood- and urine-based biomarkers could reduce these harms. To enable a comprehensive overview, we focused on SRs. These do not include the most recent prospective studies, which were therefore incorporated in the discussion., Conclusions and Clinical Implications: By identifying consistent and conflicting evidence, this review highlights the evidence-based foundations that can be built upon, as well as areas requiring further research and improvement to reduce the burden of PCa in the EU and UK., Patient Summary: This review of 26 reviews covers various aspects of prostate cancer screening such as invitation, decision-making, screening tests, harms, and benefits. This review provides insights into existing evidence, highlighting the areas of consensus and discrepancies, to guide future research and improve prostate cancer screening strategies in Europe., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
- Author
-
Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, J L H van Leenders G, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, and Cornford P
- Subjects
- Humans, Male, Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant pathology, Prostatic Neoplasms, Castration-Resistant therapy, Prostatic Neoplasms, Castration-Resistant drug therapy, Neoplasm Recurrence, Local, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy
- Abstract
Background and Objective: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines., Methods: The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence., Key Findings and Limitations: Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor-targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen-based therapy have become available for men with metastatic PCa., Conclusions and Clinical Implications: Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/)., Patient Summary: This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
46. A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer.
- Author
-
Slevin F, Zattoni F, Checcucci E, Cumberbatch MGK, Nacchia A, Cornford P, Briers E, De Meerleer G, De Santis M, Eberli D, Gandaglia G, Gillessen S, Grivas N, Liew M, Linares Espinós EE, Oldenburg J, Oprea-Lager DE, Ploussard G, Rouvière O, Schoots IG, Smith EJ, Stranne J, Tilki D, Smith CT, Van Den Bergh RCN, Van Oort IM, Wiegel T, Yuan CY, Van den Broeck T, and Henry AM
- Subjects
- Humans, Male, Treatment Outcome, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms pathology, Brachytherapy methods
- Abstract
Context: The optimum use of brachytherapy (BT) combined with external beam radiotherapy (EBRT) for localised/locally advanced prostate cancer (PCa) remains uncertain., Objective: To perform a systematic review to determine the benefits and harms of EBRT-BT., Evidence Acquisition: Ovid MEDLINE, Embase, and EBM Reviews-Cochrane Central Register of Controlled Trials databases were systematically searched for studies published between January 1, 2000 and June 7, 2022, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. Eligible studies compared low- or high-dose-rate EBRT-BT against EBRT ± androgen deprivation therapy (ADT) and/or radical prostatectomy (RP) ± postoperative radiotherapy (RP ± EBRT). The main outcomes were biochemical progression-free survival (bPFS), severe late genitourinary (GU)/gastrointestinal toxicity, metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS), at/beyond 5 yr. Risk of bias was assessed and confounding assessment was performed. A meta-analysis was performed for randomised controlled trials (RCTs)., Evidence Synthesis: Seventy-three studies were included (two RCTs, seven prospective studies, and 64 retrospective studies). Most studies included participants with intermediate-or high-risk PCa. Most studies, including both RCTs, used ADT with EBRT-BT. Generally, EBRT-BT was associated with improved bPFS compared with EBRT, but similar MFS, CSS, and OS. A meta-analysis of the two RCTs showed superior bPFS with EBRT-BT (estimated fixed-effect hazard ratio [HR] 0.54 [95% confidence interval {CI} 0.40-0.72], p < 0.001), with absolute improvements in bPFS at 5-6 yr of 4.9-16%. However, no difference was seen for MFS (HR 0.84 [95% CI 0.53-1.28], p = 0.4) or OS (HR 0.87 [95% CI 0.63-1.19], p = 0.4). Fewer studies examined RP ± EBRT. There is an increased risk of severe late GU toxicity, especially with low-dose-rate EBRT-BT, with some evidence of increased prevalence of severe GU toxicity at 5-6 yr of 6.4-7% across the two RCTs., Conclusions: EBRT-BT can be considered for unfavourable intermediate/high-risk localised/locally advanced PCa in patients with good urinary function, although the strength of this recommendation based on the European Association of Urology guideline methodology is weak given that it is based on improvements in biochemical control., Patient Summary: We found good evidence that radiotherapy combined with brachytherapy keeps prostate cancer controlled for longer, but it could lead to worse urinary side effects than radiotherapy without brachytherapy, and its impact on cancer spread and patient survival is less clear., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
- Author
-
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, and Tilki D
- Subjects
- Male, Humans, Early Detection of Cancer standards, Prostatic Neoplasms therapy, Prostatic Neoplasms pathology, Prostatic Neoplasms diagnosis
- Abstract
Background and Objective: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines provide recommendations for the management of clinically localised prostate cancer (PCa). This paper aims to present a summary of the 2024 version of the EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on the screening, diagnosis, and treatment of clinically localised PCa., Methods: The panel performed a literature review of all new data published in English, covering the time frame between May 2020 and 2023. The guidelines were updated, and a strength rating for each recommendation was added based on a systematic review of the evidence., Key Findings and Limitations: A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is considered, a combination of targeted and regional biopsies should be performed. Prostate-specific membrane antigen positron emission tomography imaging is the most sensitive technique for identifying metastatic spread. Active surveillance is the appropriate management for men with low-risk PCa, as well as for selected favourable intermediate-risk patients with International Society of Urological Pathology grade group 2 lesions. Local therapies are addressed, as well as the management of persistent prostate-specific antigen after surgery. A recommendation to consider hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term intensified hormonal treatment., Conclusions and Clinical Implications: The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. These PCa guidelines reflect the multidisciplinary nature of PCa management., Patient Summary: This article is the summary of the guidelines for "curable" prostate cancer. Prostate cancer is "found" through a multistep risk-based screening process. The objective is to find as many men as possible with a curable cancer. Prostate cancer is curable if it resides in the prostate; it is then classified into low-, intermediary-, and high-risk localised and locally advanced prostate cancer. These risk classes are the basis of the treatments. Low-risk prostate cancer is treated with "active surveillance", a treatment with excellent prognosis. For low-intermediary-risk active surveillance should also be discussed as an option. In other cases, active treatments, surgery, or radiation treatment should be discussed along with the potential side effects to allow shared decision-making., (Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
48. Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey.
- Author
-
Beyer K, Leenen RCA, Venderbos LDF, Helleman J, Remmers S, Vasilyeva V, Rivas JG, Briers E, Frese T, Vilaseca J, Vinker S, Chloupkova R, Majek O, Annemans L, Vynckier P, Basu P, Chandran A, van den Bergh R, Collen S, van Poppel H, Roobol MJ, and On Behalf Of The Praise-U Consortium
- Abstract
In 2022, the European Commission updated its recommendation on cancer screening, inviting the Member States (MSs) to explore the feasibility of stepwise implementation of population-based screening for prostate cancer (PCa). In line with this recommendation, the PRAISE-U (Prostate Cancer Awareness and Initiative for Screening in the European Union (EU)) project was initiated. As part of the PRAISE-U, we aim to understand the current practice towards early detection in the EU MSs, the barriers to implementing or planning population-based screening programmes, and potential solutions to overcome these barriers., Methods: We adapted the Barriers to Effective Screening Tool (BEST) survey to the PCa context. However, it has not been validated in this context. We translated it into all spoken languages in the EU27 and disseminated it to different stakeholders across the EU using a snowballing approach., Results: We received 410 responses from 55 countries, of which 301 (73%) were from the 27 EU MSs. The most represented stakeholder group was urologists (218 (54%)), followed by general practitioners (GPs) (83 (21%)), patient representatives (35 (9%)), policy stakeholders (27 (7%)), researchers (23 (6%)), oncologists, pathologists, radiologists, nurses, and others (16 (4%)) and one industry representative. Among all respondents, 286 (69%) reported the absence of a population-based screening programme, mainly attributed to resource limitations and a lack of political and medical society support. Out of these 286 respondents, 196 (69%) indicated that opportunistic screening is being applied in their country, and 199 (70%) expressed their support for population-based screening programmes (which was highest amongst patient representatives and urologists and lowest amongst GPs and policy stakeholders). The highest scored barriers were lack of political support, insufficient operational resources, and inadequate participation. Suggested solutions to overcome these included awareness campaigns, consensus meetings, political lobbying and European guidelines (to overcome political support barriers), compatible IT systems (to overcome operational barriers), and easy access (to overcome participation barriers)., Conclusions: Participants have noted the presence of opportunistic screening, and particularly urologists and patient representatives expressed their support for the establishment of a population-based PCa screening programme. Nevertheless, successful implementation of population-based screening programmes is complex; it requires political and medical society support, operational resources and capacity, awareness campaigns, as well as the development of protocols, guidelines, and legal frameworks.
- Published
- 2024
- Full Text
- View/download PDF
49. Reply to: Comments on "(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer".
- Author
-
Rosas JC, Aguado-Barrera ME, Azria D, Briers E, Elliott R, Farcy-Jacquet MP, Giraldo A, Gutiérrez-Enríquez S, Rancati T, Rattay T, Reyes V, Rosenstein B, De Ruysscher D, Sperk E, Stobart H, Talbot C, Vega A, Taboada-Valladares B, Veldeman L, Ward T, Webb A, West C, Chang-Claude J, and Seibold P
- Published
- 2024
- Full Text
- View/download PDF
50. How Can We Improve Patient-Clinician Communication for Men Diagnosed with Prostate Cancer?
- Author
-
Beyer K, Lawlor A, Remmers S, Bezuidenhout C, Gómez Rivas J, Venderbos LDF, Smith EJ, Gandaglia G, MacLennan S, MacLennan SJ, Bjartell A, Briganti A, Cornford P, Evans-Axelsson S, Ribal MJ, N'Dow J, Briers E, Roobol MJ, and Van Hemelrijck M
- Abstract
Background and Objective: The ability of health care professionals to communicate with patients compassionately and effectively is crucial for shared decision-making, but little research has investigated patient-clinician communication. As part of PIONEER-an international Big Data Consortium led by the European Association of Urology to answer key questions for men with prostate cancer (PCa), funded through the IMI2 Joint Undertaking under grant agreement 777492- we investigated communication between men diagnosed with PCa and the health care professional(s) treating them across Europe., Methods: We used the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Communication 26, which was shared via the PIONEER and patient organisations on March 11, 2022. We sought men who spoke French, Italian, Spanish, German, Dutch, or English who were diagnosed with PCa and were undergoing or had already received treatment for their PCa., Results and Limitations: A total of 372 men reported that they communicated with their clinician during either the diagnostic or the treatment period. Overall, the majority of participants reported positive experiences. However, important opportunities to enhance communication were identified, particularly with regard to correcting misunderstandings, understanding the patient's preferred approach to information presentation, addressing challenging questions, supporting the patient's comprehension of information, attending to the patient's emotional needs, and assessing what information had already been given to patients about their disease and treatment, and how much of it was understood., Conclusions and Clinical Implications: These results help us to identify gaps and barriers to shared treatment decision making. This knowledge will help devise measures to improve patient-health care professional communication in the PCa setting., Patient Summary: As part of the PIONEER initiative, we investigated the communication between men diagnosed with prostate cancer and their health care professionals across Europe. A total of 372 men from six different countries participated in the study. Most participants reported positive experiences, but areas where communication could be improved were identified. These included addressing misunderstandings, tailoring the presentation of information to the patient's preferences, handling difficult questions, supporting emotional needs, and assessing the patient's understanding of their diagnosis and treatment., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.